Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonates and BMU birth rate: response to comments by Ott

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ott S (2009) Bisphosphonates and BMU birth rate. Osteoporos Int doi:10.1007/s00198-009-1020-0

  2. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 1117:209–257

    Article  CAS  PubMed  Google Scholar 

  3. Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. B one 31:620–625

    CAS  Google Scholar 

  4. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteo Intern 9:489–493

    CAS  Google Scholar 

  5. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PM (1997) Histomorphometric assessment of the longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480

    Article  CAS  PubMed  Google Scholar 

  6. Bukowski JF, Dascher CC, Das H (2005) Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Comm 328:746–750

    Article  CAS  PubMed  Google Scholar 

  7. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB (2009) Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 24:597–605

    Article  CAS  PubMed  Google Scholar 

  8. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137

    Article  CAS  PubMed  Google Scholar 

  9. Boyde A, Lundy MW, Coxon FP, McKenna CE, Roelofs A, Bala J, Rogers MJ, Blazewska K, Russell RGG, Ebetino FH (2009) The differential distribution in vivo of fluorescently-labeled bisphosphonate analogues with different mineral affinity to bone surfaces abs# 204, IBMS, Sydney, Australia, Bone May 2009. Vol. 44, S57.

  10. Roelofs A J, Coxon F P, Lundy MW, Ebetino FH, Bala JF, Kashemirov BA, McKenna CE, Rogers MJ (2008) Studying cellular uptake and distribution of bisphosphonate in vivo using fluorescently-labelled analogues of risedronate. abstract 1065, 2008, ASBMR, Montreal, Canada J. Bone and Mineral Research, 23(s1):s20.

  11. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363–1374

    Article  CAS  PubMed  Google Scholar 

  12. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317–7325

    Article  CAS  PubMed  Google Scholar 

  13. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T (2008) Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23:1712–1721

    Article  CAS  PubMed  Google Scholar 

  14. Mödder UI, Khosla S (2008) Skeletal stem cell/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodelling compartment. J Cellular Biochemistry 103:393–400.

    Google Scholar 

  15. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S (2007) Remodeling and vascular spaces in bone. J Bone Miner Res 22:1–6

    Article  CAS  PubMed  Google Scholar 

  16. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147–154

    Article  CAS  PubMed  Google Scholar 

  17. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14

    Article  CAS  PubMed  Google Scholar 

  18. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphospbonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004–2011

    Article  CAS  PubMed  Google Scholar 

  19. Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast mediated resorption. Endocrinology 137:2324–2333

    Article  CAS  PubMed  Google Scholar 

  20. Evans CE, Braidman IP (1994) Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 26:95–107

    Article  CAS  PubMed  Google Scholar 

  21. Hughes DE, MacDonald BR, Russell RGG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term culture of human bone marrow. J Clin Invest 83:1930–1935

    Article  CAS  PubMed  Google Scholar 

  22. Hauge EM, Qvesel D, Eriksen EF, Mosekilde I, Melsen F (2001) Cancellous bone remodelling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16:1575–1582

    Article  CAS  PubMed  Google Scholar 

  23. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061

    Article  CAS  PubMed  Google Scholar 

  24. Santini D, Vincenzi B, Hannon RA et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15:1351–1357

    CAS  PubMed  Google Scholar 

  25. Van Beek ER, Lowick CWGM, Papapoulos SE (2002) Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30:64–70

    Article  PubMed  Google Scholar 

  26. Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737–738

    Article  CAS  PubMed  Google Scholar 

  27. Das H, Wang L, Kamath A, Bukowski JF (2001) Vg2Vd2 T-cell receptor–mediated recognition of aminobisphosphonates. Blood 98:1616–1618

    Article  CAS  PubMed  Google Scholar 

  28. Cheung MS, Glorieux FH, Rauch F (2009) Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. J Bone Miner Res 24:669–674

    Article  CAS  PubMed  Google Scholar 

  29. Wu CH, Yang YC, Yao WJ, Lu FH, Wu JS, Chang CJ (2002) Epidemiological evidence of increased bone mineral density in habitual tea drinkers. Arch Intern Med 162:1001–1006

    Article  PubMed  Google Scholar 

  30. Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF (2003) Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci 100:6009–6014

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia

    E. Seeman

Authors
  1. E. Seeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Seeman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seeman, E. Bisphosphonates and BMU birth rate: response to comments by Ott. Osteoporos Int 21, 889–890 (2010). https://doi.org/10.1007/s00198-009-1027-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1027-6

Keywords

Search

Navigation